Targeted therapy of peritoneal carcinomatosis using theranostic nanoparticles
使用治疗诊断纳米粒子靶向治疗腹膜癌病
基本信息
- 批准号:9189695
- 负责人:
- 金额:$ 41.13万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-12-04 至 2020-11-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAnimal ModelAntibodiesAntineoplastic AgentsAscitesBacterial ToxinsBiodistributionBiological AssayBiological MarkersCancer PatientCarcinomatosisCell LineChimeric ProteinsClinicalColonDetectionDevelopmentDoseDoxorubicinDrug CarriersDrug CombinationsDrug Delivery SystemsDrug KineticsDrug TargetingDrug resistanceDyesERBB2 geneEndothelial CellsEpidermal Growth Factor ReceptorEpithelial CellsEvaluationFibroblastsGoalsGreater sac of peritoneumHumanIn VitroIndustrializationInsulin-Like-Growth Factor I ReceptorIntravenousLabelLigandsLiverMagnetic Resonance ImagingMagnetismMalignant NeoplasmsMalignant neoplasm of abdomenMalignant neoplasm of ovaryMalignant neoplasm of pancreasMammary NeoplasmsMaximum Tolerated DoseMediatingMolecular TargetMonitorMusNanotechnologyNeoplasm MetastasisNude MiceOceansOperative Surgical ProceduresOrganOvarianOvaryPancreasPatient SelectionPatientsPenetrationPeptidesPeritonealPeritoneal FluidPharmaceutical PreparationsPolymersPopulationProtocols documentationQuantum DotsReceptor CellResearchResearch Project GrantsResidual TumorsSamplingSpecific qualifier valueSpecificityStomachStromal CellsStromal NeoplasmSystemTACSTD1 geneTestingTherapeuticTissuesToxinTranslational ResearchTreatment EfficacyTumor AntibodiesTumor DebulkingUniversitiesUnresectableUrokinase Plasminogen Activator ReceptorXenograft Modelabsorptionactivating transcription factorbasecellular imagingchemotherapycompanion diagnosticseffective therapyend stage diseasegastrointestinalimaging approachimprovedimproved outcomein vitro Assayin vitro testingindustry partnerintraperitonealiron oxidemacrophagemouse modelnanomedicinenanoparticleneoplastic cellnovelnovel therapeuticsoptical imagingovarian neoplasmpancreatic cancer cellspancreatic neoplasmprecision oncologypreclinical studypublic health relevancereceptorresponsespecific biomarkerssuccesssystemic toxicitytargeted biomarkertargeted cancer therapytargeted deliverytargeted treatmenttheranosticstherapeutic evaluationtherapy outcometreatment responsetumor
项目摘要
DESCRIPTION (provided by applicant): The translational goal of this Academic and Industrial Partnership research project is to develop a precision oncology protocol using a combination of novel nanotechnology biomarker profiling and intraperitoneal (i. p.) delivery of receptor-targeted theranostic nanoparticles for the effective treatment of cancer patients with massive peritoneal metastasis or peritoneal carcinomatosis (PC). The majority of PC patients not only have unresectable tumors, but also develop ascites accumulation, and are considered incurable. To address this unmet clinical challenge, we propose to develop a novel, targeted therapeutic strategy for treating PC. First, we will develop in vitro assays for the detection of the levels of
cell receptor targets and evaluation of therapeutic responses to receptor targeted theranostic nanoparticles in peritoneal tumor cells for selecting PC patients who will benefit the most from the targeted cancer therapy. Results of our preliminary studies have shown that i. p. delivery of urokinase plasminogen activator receptor (uPAR) targeted theranostic magnetic iron oxide nanoparticles (IONPs) had a high efficiency of nanoparticle delivery into orthotopic pancreatic tumors with excellent penetration deep into the tumor center, due to its ability to target tumor cells and tumor stromal endothelial cells, fibroblasts, and macrophages that mediate breakage of the tumor stromal barrier. I. p. delivery of the receptor targeted theranostic IONPs led to a marked reduction of peritoneal tumors and ascites volumes in i. p. metastatic pancreatic and ovarian cancer mouse models. Our project aims to develop a clinically feasible and new precision nanomedicine based treatment that integrates biomarker profiling and treatment response evaluation of tumor cells in peritoneal fluids with i. p. delivery of the biomarker targeted theranostic IONPs carrying a potent drug combination to enhance therapeutic responses in drug resistant i. p. tumors and therefore, improve outcome of the therapy. In Aim 1, an in vitro companion diagnostic kit for the detection of four biomarkers (uPAR, IGF1R, EGFR, and HER2) that are highly expressed in peritoneal tumors will be developed. This system includes EpCAM antibody coated IONPs (30 nm core size) for capturing tumor cells and antibody or peptide ligand conjugated quantum dots (QDs) against the above specified biomarkers. Isolation efficiency and specificity of the biomarker detection will be evaluated in ascites samples obtained from tumor-bearing mice or human PC patients. Sensitivity of enriched tumor cells to receptor targeted theranostic IONPs will be examined. Studies in Aim 2 will develop a dual agent theranostic IONP loaded with doxorubicin (Dox) and conjugated with an uPAR targeting ATF ligand fused with a bacterial toxin (PE38KDEL) and determine the therapeutic efficacy of i. p. delivery in metastatic pancreatic or ovarian tumor xenograft models in nude mice. Simultaneous delivery of a potent toxin and Dox into tumor cells has the potential to overcome chemoresistance. Finally, in Aim 3, preclinical studies on biodistribution, systemic toxicity, dose-response, and pharmacokinetics (PK) /pharmcodynamics (PD) will be conducted in normal and i. p. tumor bearing mice.
描述(由申请人提供):该学术和工业合作研究项目的转化目标是使用新型纳米技术生物标志物分析和腹膜内(即,第页)受体靶向治疗诊断纳米颗粒的递送,用于有效治疗患有大面积腹膜转移或腹膜癌病(PC)的癌症患者。大多数PC患者不仅具有不可切除的肿瘤,而且还产生腹水积聚,并且被认为是不可治愈的。为了解决这一未满足的临床挑战,我们建议开发一种新的,有针对性的治疗PC的治疗策略。首先,我们将开发用于检测以下水平的体外测定:
细胞受体靶向和评估对腹膜肿瘤细胞中受体靶向治疗诊断纳米颗粒的治疗反应,以选择将从靶向癌症治疗中获益最多的PC患者。我们的初步研究结果表明,i。尿激酶纤溶酶原激活物受体(uPAR)靶向治疗诊断磁性氧化铁纳米颗粒(IONP)的p.递送具有高效率的纳米颗粒递送到原位胰腺肿瘤中,并具有深入肿瘤中心的优异穿透性,这是由于其靶向肿瘤细胞和介导肿瘤基质屏障破坏的肿瘤基质内皮细胞、成纤维细胞和巨噬细胞的能力。I. p.递送受体靶向的治疗诊断性IONP导致i.转移性胰腺癌和卵巢癌小鼠模型。我们的项目旨在开发一种临床上可行的和新的精确的基于纳米医学的治疗方法,该方法将生物标志物分析和腹膜液中肿瘤细胞的治疗反应评估与i. p.递送携带有效药物组合的生物标志物靶向治疗诊断IONP以增强耐药性i.肿瘤,并因此改善治疗的结果。在目标1中,将开发用于检测在腹膜肿瘤中高度表达的四种生物标志物(uPAR、IGF1R、EGFR和HER2)的体外伴随诊断试剂盒。该系统包括用于捕获肿瘤细胞的EpCAM抗体包被的IONP(30 nm核尺寸)和针对上述指定生物标志物的抗体或肽配体缀合的量子点(QD)。将在从荷瘤小鼠或人PC患者获得的腹水样品中评价生物标志物检测的分离效率和特异性。将检查富集的肿瘤细胞对受体靶向治疗诊断IONP的敏感性。目的2中的研究将开发负载有多柔比星(Dox)并与融合有细菌毒素(PE 38KDEL)的uPAR靶向ATF配体缀合的双药剂治疗诊断IONP,并确定i.在裸鼠的转移性胰腺或卵巢肿瘤异种移植物模型中的腹膜内递送。同时将有效毒素和Dox递送到肿瘤细胞中具有克服化学抗性的潜力。最后,在目标3中,将在正常和i. p.荷瘤小鼠。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Hui Mao其他文献
Hui Mao的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Hui Mao', 18)}}的其他基金
Stroma penetrating and immune modulating nanoparticles for image-guided therapy of pancreatic cancer
用于胰腺癌图像引导治疗的基质穿透和免疫调节纳米颗粒
- 批准号:
10747717 - 财政年份:2023
- 资助金额:
$ 41.13万 - 项目类别:
Artificial Intelligence Driven Platform for PET/MR Imaging
人工智能驱动的 PET/MR 成像平台
- 批准号:
10652112 - 财政年份:2022
- 资助金额:
$ 41.13万 - 项目类别:
Stroma penetrating and immune modulating nanoparticles for image-guided therapy of pancreatic cancer
用于胰腺癌图像引导治疗的基质穿透和免疫调节纳米颗粒
- 批准号:
10437015 - 财政年份:2021
- 资助金额:
$ 41.13万 - 项目类别:
High-sensitivity Immunomagnetic System for "Liquid Biopsy" of Alzheimer's Disease
用于阿尔茨海默病“液体活检”的高灵敏度免疫磁系统
- 批准号:
10331820 - 财政年份:2021
- 资助金额:
$ 41.13万 - 项目类别:
Stroma penetrating and immune modulating nanoparticles for image-guided therapy of pancreatic cancer
用于胰腺癌图像引导治疗的基质穿透和免疫调节纳米颗粒
- 批准号:
10651768 - 财政年份:2021
- 资助金额:
$ 41.13万 - 项目类别:
High-sensitivity Immunomagnetic System for "Liquid Biopsy" of Alzheimer's Disease
用于阿尔茨海默病“液体活检”的高灵敏度免疫磁系统
- 批准号:
10539340 - 财政年份:2021
- 资助金额:
$ 41.13万 - 项目类别:
Stroma penetrating and immune modulating nanoparticles for image-guided therapy of pancreatic cancer
用于胰腺癌图像引导治疗的基质穿透和免疫调节纳米颗粒
- 批准号:
10249736 - 财政年份:2021
- 资助金额:
$ 41.13万 - 项目类别:
2D MR Correlational Spectroscopy Platform for Molecular and Genetic Characterizations of Glioma
用于神经胶质瘤分子和遗传特征的 2D MR 相关光谱平台
- 批准号:
9332975 - 财政年份:2017
- 资助金额:
$ 41.13万 - 项目类别:
Stroma Breaking Theranostic Nanoparticle for Targeted Pancreatic Cancer Therapy
用于靶向胰腺癌治疗的基质破坏治疗诊断纳米颗粒
- 批准号:
9750645 - 财政年份:2015
- 资助金额:
$ 41.13万 - 项目类别:
Stroma Breaking Theranostic Nanoparticle for Targeted Pancreatic Cancer Therapy
用于靶向胰腺癌治疗的基质破坏治疗诊断纳米颗粒
- 批准号:
8959819 - 财政年份:2015
- 资助金额:
$ 41.13万 - 项目类别:
相似国自然基金
一株抗人B组腺病毒广谱中和单抗的人源化改造及评价动物模型的建立
- 批准号:n/a
- 批准年份:2023
- 资助金额:10.0 万元
- 项目类别:省市级项目
TLR4调控系统性红斑狼疮中自身反应性B-1a细胞活化的作用及机理研究
- 批准号:81901635
- 批准年份:2019
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
抗艾滋病毒广谱中和抗体生成模型研究
- 批准号:81873963
- 批准年份:2018
- 资助金额:81.0 万元
- 项目类别:面上项目
IL-17促进系统性红斑狼疮发病中浆细胞功能的机制研究
- 批准号:81771761
- 批准年份:2017
- 资助金额:60.0 万元
- 项目类别:面上项目
中东呼吸综合征新型人源应急救治单克隆抗体保护作用机制研究
- 批准号:81772191
- 批准年份:2017
- 资助金额:56.0 万元
- 项目类别:面上项目
抗磷脂抗体诱导中性粒细胞释放NETs致抗磷脂综合征肾病的机制研究
- 批准号:81671589
- 批准年份:2016
- 资助金额:57.0 万元
- 项目类别:面上项目
肺腺癌中Timp-1促癌机制的研究及其阻断抗体的运用
- 批准号:81672268
- 批准年份:2016
- 资助金额:57.0 万元
- 项目类别:面上项目
抗体的体细胞超变在鼠狼疮性肾炎形成中的作用及机制研究
- 批准号:31270916
- 批准年份:2012
- 资助金额:85.0 万元
- 项目类别:面上项目
新的恒河猴自身免疫性糖尿病模型的建立及相关机理研究
- 批准号:81200617
- 批准年份:2012
- 资助金额:32.0 万元
- 项目类别:青年科学基金项目
系统性硬化症外周血及肺脏microRNA表达谱及功能研究
- 批准号:81102268
- 批准年份:2011
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
- 批准号:
495434 - 财政年份:2023
- 资助金额:
$ 41.13万 - 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
- 批准号:
10642519 - 财政年份:2023
- 资助金额:
$ 41.13万 - 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
- 批准号:
10586596 - 财政年份:2023
- 资助金额:
$ 41.13万 - 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
- 批准号:
10590479 - 财政年份:2023
- 资助金额:
$ 41.13万 - 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
- 批准号:
23K06011 - 财政年份:2023
- 资助金额:
$ 41.13万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
- 批准号:
10682117 - 财政年份:2023
- 资助金额:
$ 41.13万 - 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
- 批准号:
10708517 - 财政年份:2023
- 资助金额:
$ 41.13万 - 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
- 批准号:
10575566 - 财政年份:2023
- 资助金额:
$ 41.13万 - 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
- 批准号:
23K15696 - 财政年份:2023
- 资助金额:
$ 41.13万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
- 批准号:
23K15867 - 财政年份:2023
- 资助金额:
$ 41.13万 - 项目类别:
Grant-in-Aid for Early-Career Scientists